Literature DB >> 21050875

Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.

Illana Gozes1.   

Abstract

NAP (davunetide) is an active fragment of activity-dependent neuroprotective protein (ADNP). ADNP and the homologous protein ADNP2 provide cell protection. ADNP is essential for brain formation, proper development and neuronal plasticity, all reported to be impaired in schizophrenia. ADNP haploinsufficiecy inhibits social and cognitive functions, major hallmarks in schizophrenia. Imbalance in ADNP/ADNP2 expression in the schizophrenia brain may impact disease progression. NAP treatment partly ameliorates ADNP haploinsufficiecy. The microtubule, stable tubule-only polypeptide (STOP)-deficient mice were shown to provide a reliable model for schizophrenia. Daily intranasal NAP treatment significantly decreased hyperactivity in STOP-deficient mice and protected visual memory, supporting further clinical development. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21050875     DOI： 10.1016/j.peptides.2010.10.030

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  6 in total

1.  Mutations in ADNP affect expression and subcellular localization of the protein.

Authors:  Elisa Cappuyns; Jolien Huyghebaert; Geert Vandeweyer; R Frank Kooy
Journal:  Cell Cycle       Date:  2018-07-17       Impact factor: 4.534

2.  Pathology of white matter integrity in three major white matter fasciculi: A post-mortem study of schizophrenia and treatment status.

Authors:  Kirsten E Schoonover; Charlene B Farmer; Andrew E Cash; Rosalinda C Roberts
Journal:  Br J Pharmacol       Date:  2019-03-18       Impact factor: 8.739

3.  Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Authors:  L Fredrik Jarskog; Zhengchao Dong; Alayar Kangarlu; Tiziano Colibazzi; Ragy R Girgis; Lawrence S Kegeles; Deanna M Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; Michael P Harms; Daniel C Javitt; Richard Se Keefe; Joseph P McEvoy; Robert P McMahon; Stephen R Marder; Bradley S Peterson; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2013-01-16       Impact factor: 7.853

4.  Understanding schizophrenia as a disorder of consciousness: biological correlates and translational implications from quantum theory perspectives.

Authors:  Ganesan Venkatasubramanian
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

Review 5.  Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.

Authors:  Mark J Millan; Yves Agid; Martin Brüne; Edward T Bullmore; Cameron S Carter; Nicola S Clayton; Richard Connor; Sabrina Davis; Bill Deakin; Robert J DeRubeis; Bruno Dubois; Mark A Geyer; Guy M Goodwin; Philip Gorwood; Thérèse M Jay; Marian Joëls; Isabelle M Mansuy; Andreas Meyer-Lindenberg; Declan Murphy; Edmund Rolls; Bernd Saletu; Michael Spedding; John Sweeney; Miles Whittington; Larry J Young
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

6.  The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism.

Authors:  Geert Vandeweyer; Céline Helsmoortel; Anke Van Dijck; Anneke T Vulto-van Silfhout; Bradley P Coe; Raphael Bernier; Jennifer Gerdts; Liesbeth Rooms; Jenneke van den Ende; Madhura Bakshi; Meredith Wilson; Ann Nordgren; Laura G Hendon; Omar A Abdulrahman; Corrado Romano; Bert B A de Vries; Tjitske Kleefstra; Evan E Eichler; Nathalie Van der Aa; R Frank Kooy
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-08-28       Impact factor: 3.908
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.